- Corticosteroids
- Monoclonal Antibodies (mAbs)
- Calcineurin Inhibitors
- mTOR Inhibitors
- Anti-Proliferative Agents
- Others
Immunosuppressants Market size was valued at USD 61.54 billion in 2022 and is poised to grow at a CAGR of 14.2% from 2023-2029. Immunosuppressants or anti-rejections are the medicinal substances, which prevent or inhibit the immune system activity. Immunosuppressants are most commonly used in the organ transplantation, autoimmune disorders such as Crohn’s disease, multiple sclerosis, rheumatoid arthritis, and among others. Moreover, immunosuppressants also used in some non-autoimmune inflammatory diseases such as ankylosing spondylitis. Immunodeficiency is the major adverse effect associated with the immunosuppressants as these drugs act non-selectively and increase the susceptibility to infections. In addition, dyslipidemia, peptic ulcers, hypertension, kidney injury, hyperglycemia, and hepatic injuries are other adverse effects with the immunosuppressants. Immunosuppressants market is growing at a significant CAGR owing to increase in the prevalence of autoimmune disorders and incidence of organ transplantation. For instance, According to World Health Organization, in 2014, approximately 119,873 organ transplantation cases were observed, which was increased about 1.8% from 2013. Furthermore, various pipeline products in the market also expected to bolster the market over the forecast period. Acquisitions & mergers, collaborations, and product launches are the strategies followed by the companies for increasing their revenue in immunosuppressants market.
Study Period
Base Year
CAGR
Largest Market
Fastest Growing Market
Increase in the incidence of organ failure and there by rising demand for organ transplantation, technological advancements in organ transplantation procedures, and increase in the prevalence of autoimmune diseases are the factors anticipated to fuel the immunosuppressants market over the forecast period. Moreover, favourable reimbursement policies for immunosuppressants, development of newer therapeutic drugs, and various pipeline products might fuel the immunosuppressants market over the forecast period. However, stringent regulatory policies for drug approval, alternative therapies such as stem cell therapy for immunosuppression, and lack of awareness about immunosuppressants are the factors expected to hamper the growth of immunosuppressants market over the forecast period.
The immunosuppressants market size was valued at USD 61.54 billion in 2022
Technological Advancements in Tissue Engineering and Organ Transplantations
Asia Pacific is the fastest-growing for immunosuppressants market
1. Executive Summary |
2. Global Immunosuppressants Market Introduction |
2.1.Global Immunosuppressants Market - Taxonomy |
2.2.Global Immunosuppressants Market - Definitions |
2.2.1.By Drug Class |
2.2.2.By Indication |
2.2.3.By Route Administration |
2.2.4.By Distribution Channel |
2.2.5.By Region |
3. Global Immunosuppressants Market Dynamics |
3.1. Drivers |
3.2. Restraints |
3.3. Opportunities/Unmet Needs of the Market |
3.4. Trends |
3.5. Product Landscape |
3.6. New Product Launches |
3.7. Impact of COVID 19 on Market |
4. Global Immunosuppressants Market Analysis, 2018 - 2022 and Forecast 2023 - 2029 |
4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) |
4.3. Market Opportunity Analysis |
5. Global Immunosuppressants Market By Drug Class, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
5.1. Corticosteroids |
5.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.1.3. Market Opportunity Analysis |
5.2. Monoclonal Antibodies (mAbs) |
5.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.2.3. Market Opportunity Analysis |
5.3. Calcineurin Inhibitors |
5.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.3.3. Market Opportunity Analysis |
5.4. mTOR Inhibitors |
5.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
5.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.4.3. Market Opportunity Analysis |
5.5. Anti-Proliferative Agents |
5.5.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
5.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.5.3. Market Opportunity Analysis |
5.6. Others |
5.6.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
5.6.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.6.3. Market Opportunity Analysis |
6. Global Immunosuppressants Market By Indication, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
6.1. Organ Transplantation |
6.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.1.3. Market Opportunity Analysis |
6.2. Autoimmune Disorders |
6.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.2.3. Market Opportunity Analysis |
6.3. Non-Autoimmune Inflammatory Diseases |
6.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.3.3. Market Opportunity Analysis |
7. Global Immunosuppressants Market By Route Administration, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
7.1. Oral |
7.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.1.3. Market Opportunity Analysis |
7.2. Parenteral |
7.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.2.3. Market Opportunity Analysis |
8. Global Immunosuppressants Market By Distribution Channel, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
8.1. Hospital pharmacies |
8.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.1.3. Market Opportunity Analysis |
8.2. Retail pharmacies |
8.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.2.3. Market Opportunity Analysis |
8.3. Online pharmacies |
8.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.3.3. Market Opportunity Analysis |
9. Global Immunosuppressants Market By Region, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
9.1. North America |
9.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
9.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
9.1.3. Market Opportunity Analysis |
9.2. Europe |
9.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
9.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
9.2.3. Market Opportunity Analysis |
9.3. Asia Pacific (APAC) |
9.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
9.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
9.3.3. Market Opportunity Analysis |
9.4. Middle East and Africa (MEA) |
9.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
9.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
9.4.3. Market Opportunity Analysis |
9.5. Latin America |
9.5.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
9.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
9.5.3. Market Opportunity Analysis |
10. North America Immunosuppressants Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
10.1. Drug Class Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.1.1.Corticosteroids |
10.1.2.Monoclonal Antibodies (mAbs) |
10.1.3.Calcineurin Inhibitors |
10.1.4.mTOR Inhibitors |
10.1.5.Anti-Proliferative Agents |
10.1.6.Others |
10.2. Indication Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.2.1.Organ Transplantation |
10.2.2.Autoimmune Disorders |
10.2.3.Non-Autoimmune Inflammatory Diseases |
10.3. Route Administration Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.3.1.Oral |
10.3.2.Parenteral |
10.4. Distribution Channel Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.4.1.Hospital pharmacies |
10.4.2.Retail pharmacies |
10.4.3.Online pharmacies |
10.5. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.5.1.United States of America (USA) |
10.5.2.Canada |
11. Europe Immunosuppressants Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
11.1. Drug Class Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.1.1.Corticosteroids |
11.1.2.Monoclonal Antibodies (mAbs) |
11.1.3.Calcineurin Inhibitors |
11.1.4.mTOR Inhibitors |
11.1.5.Anti-Proliferative Agents |
11.1.6.Others |
11.2. Indication Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.2.1.Organ Transplantation |
11.2.2.Autoimmune Disorders |
11.2.3.Non-Autoimmune Inflammatory Diseases |
11.3. Route Administration Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.3.1.Oral |
11.3.2.Parenteral |
11.4. Distribution Channel Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.4.1.Hospital pharmacies |
11.4.2.Retail pharmacies |
11.4.3.Online pharmacies |
11.5. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.5.1.Germany |
11.5.2.France |
11.5.3.Italy |
11.5.4.United Kingdom (UK) |
11.5.5.Spain |
11.5.6.Rest of EU |
11.5.7. |
12. Asia Pacific (APAC) Immunosuppressants Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
12.1. Drug Class Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.1.1.Corticosteroids |
12.1.2.Monoclonal Antibodies (mAbs) |
12.1.3.Calcineurin Inhibitors |
12.1.4.mTOR Inhibitors |
12.1.5.Anti-Proliferative Agents |
12.1.6.Others |
12.2. Indication Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.2.1.Organ Transplantation |
12.2.2.Autoimmune Disorders |
12.2.3.Non-Autoimmune Inflammatory Diseases |
12.3. Route Administration Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.3.1.Oral |
12.3.2.Parenteral |
12.4. Distribution Channel Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.4.1.Hospital pharmacies |
12.4.2.Retail pharmacies |
12.4.3.Online pharmacies |
12.5. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.5.1.China |
12.5.2.India |
12.5.3.Australia and New Zealand (ANZ) |
12.5.4.Japan |
12.5.5.Rest of APAC |
13. Middle East and Africa (MEA) Immunosuppressants Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
13.1. Drug Class Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.1.1.Corticosteroids |
13.1.2.Monoclonal Antibodies (mAbs) |
13.1.3.Calcineurin Inhibitors |
13.1.4.mTOR Inhibitors |
13.1.5.Anti-Proliferative Agents |
13.1.6.Others |
13.2. Indication Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.2.1.Organ Transplantation |
13.2.2.Autoimmune Disorders |
13.2.3.Non-Autoimmune Inflammatory Diseases |
13.3. Route Administration Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.3.1.Oral |
13.3.2.Parenteral |
13.4. Distribution Channel Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.4.1.Hospital pharmacies |
13.4.2.Retail pharmacies |
13.4.3.Online pharmacies |
13.5. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.5.1.GCC Countries |
13.5.2.South Africa |
13.5.3.Rest of MEA |
14. Latin America Immunosuppressants Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
14.1. Drug Class Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
14.1.1.Corticosteroids |
14.1.2.Monoclonal Antibodies (mAbs) |
14.1.3.Calcineurin Inhibitors |
14.1.4.mTOR Inhibitors |
14.1.5.Anti-Proliferative Agents |
14.1.6.Others |
14.2. Indication Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
14.2.1.Organ Transplantation |
14.2.2.Autoimmune Disorders |
14.2.3.Non-Autoimmune Inflammatory Diseases |
14.3. Route Administration Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
14.3.1.Oral |
14.3.2.Parenteral |
14.4. Distribution Channel Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
14.4.1.Hospital pharmacies |
14.4.2.Retail pharmacies |
14.4.3.Online pharmacies |
14.5. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
14.5.1.Brazil |
14.5.2.Mexico |
14.5.3.Rest of LA |
15. Competition Landscape |
15.1. Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) |
15.2.1.GlaxoSmithKline Plc. (U.K.) |
15.2.2.Novartis AG (Switzerland) |
15.2.3.Sanofi S.A. (France) |
15.2.4.Pfizer, Inc. (U.S.) |
15.2.5.Bristol Myers Squibb (U.S.) |
15.2.6.F. Hoffmann La Roche Ltd. (Switzerland) |
15.2.7.Astellas Pharma, Inc. (Japan) |
15.2.8.Zydus Cadila (India) |
16. Research Methodology |
17. Appendix and Abbreviations |